Drug major Merck (MRK) announced Monday that its spinoff Organon is expected to drive sustainable growth and shareholder value as a standalone company focused on women's health.
The initial portfolio of Organon, which will be launched on June 3 as a new company, is expected to generate low to mid-single organic revenue growth off of a 2021 base. At launch, Organon's portfolio will consist of more than 60 medicines and products across its three core franchises: Women's Health, Biosimilars and Established Brands.
Merck is hosting Organon Investor Day today, detailing plans with solid growth opportunities and the ability to make an impact in women's health.
Rob Davis, president, Merck, said, "The spinoff of Organon will help Merck become a leaner, more focused and agile company with stronger growth, and will enable significant operating efficiencies."
Organon is expected to have a global footprint with significant scale and geographic reach, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.